WT1 expression in the female genital tract

Advances in Anatomic Pathology

Volumn 18, Issue 6, 2011, Pages 454-465

  Bárcena, Carmen ^a   Oliva, Esther ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

differential diagnosis; female genital tract; immunohistochemistry; WT1

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADENOMATOID TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; ENDOMETRIAL SEROUS CARCINOMA; ENDOMETRIAL STROMAL TUMOR; ENDOMETRIUM CARCINOMA; EPITHELIAL TUMOR OF THE OVARY; EPITHELIUM TUMOR; FEMALE GENITAL TRACT TUMOR; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MALIGNANT MESOTHELIOMA; MESENCHYMAL TUMOR OF THE UTERUS; MESODERMAL ADENOSARCOMA; MIXED TUMOR; OVARIAN SMALL CELL CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; SEX CORD TUMOR; SMALL CELL SARCOMA; TRANSITIONAL CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA OF THE OVARY; TUMOR SUPPRESSOR GENE; UTERUS TUMOR;

CARCINOMA, ENDOMETRIOID; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENITALIA, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SEX CORD-GONADAL STROMAL TUMORS; UTERINE NEOPLASMS; WT1 PROTEINS;

EID: 80054697021     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e318234aaed     Document Type: Review

References (205)

1. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990;60:509-520.
2. Gessler M, Poustka A, Cavenee W, et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature. 1990;343:774-778.
3. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature. 1990;346:194-197.
4. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res. 2001;264:74-99. (Pubitemid 32989083)
5. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90:194-204. (Pubitemid 29112320)
6. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res. 2002;8:1167-1171. (Pubitemid 34517654)
7. Silberstein GB, van Horn K, Strickland P, et al. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci U S A. 1997;94:8132-8137. (Pubitemid 27343789)
8. Loeb DM, Evron E, Patel CB, et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 2001;61:921-925. (Pubitemid 32174404)
9. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89:1405-1412. (Pubitemid 27080005)
10. Davies JA. Mesenchyme to epithelium transition during development of the mammalian kidney tubule. Acta Anat (Basel). 1996;156:187-201. (Pubitemid 27072575)
11. Hosono S, Luo X, Hyink DP, et al. WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts. Oncogene. 1999;18:417-427. (Pubitemid 29060617)
12. Okamoto S, Okamoto A, Nikaido T, et al. Mesenchymal to epithelial transition in the human ovarian surface epithelium focusing on inclusion cysts. Oncol Rep. 2009;21:1209-1214.
13. Hill DA, Pfeifer JD, Marley EF, et al. WT1 staining reliably differentiates desmoplastic small round cell tumor from Ewing sarcoma/primitive neuroectodermal tumor: an immunohistochemical and molecular diagnostic study. Am J Clin Pathol. 2000;114:345-353. (Pubitemid 33049669)
14. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene. 2001;273:141-161. (Pubitemid 32786908)
15. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia. 1992;6:405-409.
16. Al-Adnani M, Williams S, Anderson J, et al. Immunohistochemical nuclear positivity for WT1 in childhood acute myeloid leukemia. Fetal Pediatr Pathol. 2007;26:193-197. (Pubitemid 350256161)
17. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell. 1990;61:1257-1269.
18. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol. 2001;116:246-252. (Pubitemid 33044330)
19. Park S, Schalling M, Bernard A, et al. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet. 1993;4:415-420. (Pubitemid 23231493)
20. Schorge JO, Miller YB, Qi LJ, et al. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol. 2000;76:369-372. (Pubitemid 30131509)
21. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163. (Pubitemid 30212153)
22. Bepler G, Garcia-Blanco MA. Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc Natl Acad Sci U S A. 1994;91:5513-5517.
23. He H, Luthringer DJ, Hui P, et al. Expression of CD56 and WT1 in ovarian stroma and ovarian stromal tumors. Am J Surg Pathol. 2008;32:884-890.
24. Patil DT, Laskin WB, Fetsch JF, et al. Inguinal smooth muscle tumors in women-a dichotomous group consisting of Mullerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases. Am J Surg Pathol. 2011;35:315-324.
25. Ordoñez NG. Desmoplastic small round cell tumor: II: an ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers. Am J Surg Pathol. 1998;22:1314-1327. (Pubitemid 28499122)
26. Carpentieri DF, Nichols K, Chou PM, et al. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod Pathol. 2002;15:1080-1086.
27. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804-814. (Pubitemid 43780450)
28. Pelletier J, Schalling M, Buckler AJ, et al. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev. 1991;5:1345-1356. (Pubitemid 21906043)
29. Makrigiannakis A, Coukos G, Mantani A, et al. Expression of Wilms' tumor suppressor gene (WT1) in human endometrium: regulation through decidual differentiation. J Clin Endocrinol Metab. 2001;86:5964-5972. (Pubitemid 33152650)
30. Koonings PP, Campbell K, Mishell DR Jr, et al. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921-926. (Pubitemid 20003288)
31. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109-115. (Pubitemid 38296970)
32. O'Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29:1034-1041. (Pubitemid 41045547)
33. Gershenson DM, Silva EG, Mitchell MF, et al. Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. Am J Obstet Gynecol. 1993;168:1178-1185; discussion 1185-1177.
34. Kommoss F, Kommoss S, Schmidt D, et al. Survival benefit for patients with advanced-stage transitional cell carcinomas versus other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol. 2005;97:195-199. (Pubitemid 40403694)
35. Silva EG, Robey-Cafferty SS, Smith TL, et al. Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol. 1990;93:457-465. (Pubitemid 20128839)
36. Robey SS, Silva EG, Gershenson DM, et al. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer. 1989;63:839-847. (Pubitemid 19063188)
37. Costa MJ, Hansen C, Dickerman A, et al. Clinicopathologic significance of transitional cell carcinoma pattern in nonlocalized ovarian epithelial tumors (stages 2-4). Am J Clin Pathol. 1998;109:173-180. (Pubitemid 28074367)
38. Hollingsworth HC, Steinberg SM, Silverberg SG, et al. Advanced stage transitional cell carcinoma of the ovary. Hum Pathol. 1996;27:1267-1272. (Pubitemid 26415317)
39. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol. 2004;28:453-463. (Pubitemid 38436518)
40. Gershenson DM, Baker VV, Price JE, et al. Molecular profile of advanced-stage transitional cell carcinoma of the ovary. Am J Obstet Gynecol. 1997;177:120-125. (Pubitemid 27327322)
41. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol. 2003;27:1434-1441. (Pubitemid 37315195)
42. Liao XY, Xue WC, Shen DH, et al. p63 expression in ovarian tumours: a marker for Brenner tumours but not transitional cell carcinomas. Histopathology. 2007;51:477-483. (Pubitemid 47439825)
43. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27:161-174. (Pubitemid 351450675)
44. Irving JA, Catasus L, Gallardo A, et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol. 2005;36:605-619. (Pubitemid 40922566)
45. Catasus L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol. 2004;35:1360-1368. (Pubitemid 39601576)
46. Moreno-Bueno G, Gamallo C, Perez-Gallego L, et al. Betacatenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol. 2001;10:116-122. (Pubitemid 32525880)
47. Oliva E, Sarrio D, Brachtel EF, et al. High frequency of betacatenin mutations in borderline endometrioid tumours of the ovary. J Pathol. 2006;208:708-713.
48. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004;23:110-118. (Pubitemid 38391769)
49. Tangjitgamol S, Manusirivithaya S, Khunnarong J, et al. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer. 2009;19:620-627.
50. Geyer JT, Lopez-Garcia MA, Sanchez-Estevez C, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol. 2009;33:1157-1163.
51. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117:541-545. (Pubitemid 34823682)
52. McCluggage WG, Oliva E, Connolly LE, et al. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. Int J Gynecol Pathol. 2004;23:330-336. (Pubitemid 39299021)
53. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152-163. (Pubitemid 351218874)
54. O'Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumor. Histopathology. 2007;50:773-779. (Pubitemid 46683935)
55. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and highgrade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problem. Adv Anat Pathol. 2009;16:267-282.
56. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14-21.
57. Tavassoli F. World Health Organization Classification of Tumours Pathology and Genetics of Tumors of Breast and Female Genital Organs. Lyon: IARC Press; 2003.
58. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology. 2007;39:134-138.
59. Silva EG, Tornos C, Bailey MA, et al. Undifferentiated carcinoma of the ovary. Arch Pathol Lab Med. 1991;115:377-381.
60. Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23:781-789.
61. Altrabulsi B, Malpica A, Deavers MT, et al. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29:1316-1321. (Pubitemid 41368767)
62. Resnik E, Taxy JB. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol. 1996;62:123-127. (Pubitemid 26234557)
63. Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol. 2004;94:456-462. (Pubitemid 39024553)
64. DiCioccio RA, Werness BA, Peng R, et al. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet. 1998;105:93-102. (Pubitemid 28381620)
65. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A. 1993;90:4961-4965. (Pubitemid 23182955)
66. Leitao MM, Soslow RA, Baergen RN, et al. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol. 2004;93:301-306. (Pubitemid 38507593)
67. Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993;53:3103-3108. (Pubitemid 23210320)
68. Euscher ED, Malpica A, Deavers MT, et al. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol. 2005;29:1074-1078. (Pubitemid 41045553)
69. Nofech-Mozes S, Khalifa MA, Ismiil N, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol. 2008;21:1147-1155.
70. Zhang Q, Wright T, Alexis D, et al. Differential expression of WT1 in uterine serous and endometrioid carcinoma. Mod Pathol. 2003;16:217A.
71. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408. (Pubitemid 27208598)
72. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950;3:74-85.
73. Hajdu SI, Urban JA. Cancers metastatic to the breast. Cancer. 1972;29:1691-1696.
74. Khalifeh I, Deavers MT, Cristofanilli M, et al. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J. 2009;15:176-181.
75. Recine MA, Deavers MT, Middleton LP, et al. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. Am J Surg Pathol. 2004;28:1646-1651. (Pubitemid 39564972)
76. Lee AH. The histological diagnosis of metastases to the breast from extramammary malignancies. J Clin Pathol. 2007;60:1333-1341. (Pubitemid 350247249)
77. Lee AH, Paish EC, Marchio C, et al. The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. Histopathology. 2007;51:824-828. (Pubitemid 350179419)
78. Kim MJ, Gong G, Joo HJ, et al. Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component. Arch Pathol Lab Med. 2005;129:1277-1282. (Pubitemid 41407433)
79. Pettinato G, Manivel CJ, Panico L, et al. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol. 2004;121:857-866. (Pubitemid 38669280)
80. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer. 2002;38:758-763. (Pubitemid 34280319)
81. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403-439. (Pubitemid 34535443)
82. Kanner WA, Galgano MT, Stoler MH, et al. Distinguishing breast carcinoma from Mullerian serous carcinoma with mammaglobin and mesothelin. Int J Gynecol Pathol. 2008;27:491-495.
83. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005;29:1482-1489. (Pubitemid 41513298)
84. Lotan TL, Ye H, Melamed J, et al. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. 2009;33:1037-1041.
85. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
86. Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol. 2004;12:122-126. (Pubitemid 38788760)
87. Lee BH, Hecht JL, Pinkus JL, et al. WT1 estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750. (Pubitemid 34457009)
88. (a) Mani H, Merino MJ. Mesothelial neoplasms presenting as, and mimicking, ovarian cancer. Int J Gynecol Pathol. 2010;29:523-528.
89. (b) Clement PB, Young RH, Scully RE. Malignant mesothelioma presenting as ovarian masses. A report of nine cases. Am J Surg Pathol. 1996;20:1067-1080.
90. Barnetson RJ, Burnett RA, Downie I, et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol. 2006;125:67-76. (Pubitemid 43089727)
91. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110. (Pubitemid 40128102)
92. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139-1148. (Pubitemid 47207115)
93. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162-2169. (Pubitemid 40490123)
94. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847-853. (Pubitemid 43780455)
95. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
96. Ordoñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22:1203-1214. (Pubitemid 28462768)
97. Takeshima Y, Amatya VJ, Kushitani K, et al. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol. 2008;130:771-779.
98. Ordoñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051. (Pubitemid 36909525)
99. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36:341-347. (Pubitemid 30198916)
100. Ordoñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606. (Pubitemid 30180755)
101. Foster MR, Johnson JE, Olson SJ, et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med. 2001;125:1316-1320. (Pubitemid 32976753)
102. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol. 2004;23:97-99. (Pubitemid 38391767)
103. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627-635.
104. Huang CC, Chang DY, Chen CK, et al. Adenomatoid tumor of the female genital tract. Int J Gynaecol Obstet. 1995;50:275-280.
105. Nogales FF, Isaac MA, Hardisson D, et al. Adenomatoid tumors of the uterus: an analysis of 60 cases. Int J Gynecol Pathol. 2002;21:34-40. (Pubitemid 34008351)
106. Tiltman AJ. Adenomatoid tumours of the uterus. Histopathology. 1980;4:437-443. (Pubitemid 10037077)
107. Young RH, Silva EG, Scully RE. Ovarian and juxtaovarian adenomatoid tumors: a report of six cases. Int J Gynecol Pathol. 1991;10:364-371.
108. Youngs LA, Taylor HB. Adenomatoid tumors of the uterus and fallopian tube. Am J Clin Pathol. 1967;48:537-545.
109. Schwartz EJ, Longacre TA. Adenomatoid tumors of the female and male genital tracts express WT1. Int J Gynecol Pathol. 2004;23:123-128. (Pubitemid 38391771)
110. Deavers MT, Silva EG, Euscher ED, et al. WT1 expression may differentiate mullerian from non-mullerian smooth muscle tumors. Modern Pathology. 2006;19:176A.
111. Che M, Tornos C, Deavers MT, et al. Ovarian mixedepithelial carcinomas with a microcystic pattern and signetring cells. Int J Gynecol Pathol. 2001;20:323-328. (Pubitemid 32937445)
112. Dickersin GR, Young RH, Scully RE. Signet-ring stromal and related tumors of the ovary. Ultrastruct Pathol. 1995;19:401-419.
113. Irving JA, Young RH. Microcystic stromal tumor of the ovary: report of 16 cases of a hitherto uncharacterized distinctive ovarian neoplasm. Am J Surg Pathol. 2009;33:367-375.
114. Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol. 2006;30:277-299. (Pubitemid 43740160)
115. Phillips V, McCluggage WG, Young RH. Oxyphilic adenomatoid tumor of the ovary: a case report with discussion of the differential diagnosis of ovarian tumors with vacuoles and related spaces. Int J Gynecol Pathol. 2007;26:16-20. (Pubitemid 46036953)
116. Zhao C, Bratthauer GL, Barner R, et al. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor. Am J Surg Pathol. 2007;31:1378-1386. (Pubitemid 47329675)
117. Oliva E, Clement PB, Young RH, et al. Mixed endometrial stromal and smooth muscle tumors of the uterus. A clinicopathologic study of 15 cases. Am J Surg Pathol. 1998;22:997-1005. (Pubitemid 28364500)
118. Oliva E, Clement PB, Young RH. Epithelioid endometrial and endometrioid stromal tumors: a report of four cases emphasizing their distinction from epithelioid smooth muscle tumors and other oxyphilic uterine and extrauterine tumors. Int J Gynecol Pathol. 2002;21:48-55. (Pubitemid 34008353)
119. Oliva E, Young RH, Clement PB, et al. Cellular benign mesenchymal tumors of the uterus. A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and six endometrial stromal nodules, two frequently confused tumors. Am J Surg Pathol. 1995;19:757-768.
120. Oliva E, Young RH, Clement PB, et al. Myxoid and fibrous endometrial stromal tumors of the uterus: a report of 10 cases. Int J Gynecol Pathol. 1999;18:310-319. (Pubitemid 29489051)
121. Scully RE. Smooth-muscle differentiation in genital tract disorders. Arch Pathol Lab Med. 1981;105:505-507. (Pubitemid 11000114)
122. Tavassoli FA, Norris HJ. Mesenchymal tumours of the uterus. VII: a clinicopathological study of 60 endometrial stromal nodules. Histopathology. 1981;5:1-10. (Pubitemid 11052494)
123. Sumathi VP, Al-Hussaini M, Connolly LE, et al. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody. Int J Gynecol Pathol. 2004;23:241-247. (Pubitemid 38857112)
124. Agoff SN, Grieco Versus, Garcia R, et al. Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma. Appl Immunohistochem Mol Morphol. 2001;9:164-169. (Pubitemid 32477204)
125. Chu PG, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol. 2001;14:465-471. (Pubitemid 32448746)
126. Devaney K, Tavassoli FA. Immunohistochemistry as a diagnostic aid in the interpretation of unusual mesenchymal tumors of the uterus. Mod Pathol. 1991;4:225-231.
127. Farhood AI, Abrams J. Immunohistochemistry of endometrial stromal sarcoma. Hum Pathol. 1991;22:224-230.
128. Franquemont DW, Frierson HF Jr., Mills SE. An immunohistochemical study of normal endometrial stroma and endometrial stromal neoplasms. Evidence for smooth muscle differentiation. Am J Surg Pathol. 1991;15:861-870.
129. Oliva E. CD10 expression in the female genital tract: Does it have useful diagnostic applications? Adv Anat Pathol. 2004;11:310-315.
130. Nucci MR, O'Connell JT, Huettner PC, et al. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol. 2001;25:455-463. (Pubitemid 32240884)
131. Rush DS, Tan J, Baergen RN, et al. h-Caldesmon a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol. 2001;25:253-258. (Pubitemid 32167508)
132. Carvalho JC, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups. Cancer. 2009;115:4186-4195.
133. Lee CH, Turbin DA, Sung YC, et al. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol. 2009;22:1519-1531.
134. Clement PB, Scully RE. Uterine tumors resembling ovarian sex-cord tumors: a clinicopathologic analysis of fourteen cases. Am J Clin Pathol. 1976;66:512-525.
135. Baker RJ, Hildebrandt RH, Rouse RV, et al. Inhibin and CD99 (MIC2) expression in uterine stromal neoplasms with sex-cord-like elements. Hum Pathol. 1999;30:671-679. (Pubitemid 29266727)
136. Czernobilsky B, Mamet Y, David MB, et al. Uterine retiform sertoli-leydig cell tumor: report of a case providing additional evidence that uterine tumors resembling ovarian sex cord tumors have a histologic and immunohistochemical phenotype of genuine sex cord tumors. Int J Gynecol Pathol. 2005;24:335-340. (Pubitemid 41368285)
137. de Leval L, Lim GS, Waltregny D, et al. Diverse phenotypic profile of uterine tumors resembling ovarian sex cord tumors: an immunohistochemical study of 12 cases. Am J Surg Pathol. 2010;34:1749-1761.
138. Zamechik M, Stanik M, Michal M. Smooth muscle/myoid differentiation in utrerine tumor resembling ovarian sex cord tumor (UTROSCT). Histopathology. 2009;55:619-620.
139. Fekete PS, Vellios F, Patterson BD. Uterine tumor resembling an ovarian sex-cord tumor: report of a case of an endometrial stromal tumor with foam cells and ultrastructural evidence of epithelial differentiation. Int J Gynecol Pathol. 1985;4:378-387. (Pubitemid 16175337)
140. Gupta M, de Leval L, Selig M, et al. Uterine tumors resembling ovarian sex cord tumors: an ultrastructural analysis of 13 cases. Ultrastruct Pathol. 2010;34:16-24.
141. Hurrell DP, McCluggage WG. Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers. J Clin Pathol. 2007;60:1148-1154. (Pubitemid 47612650)
142. Irving JA, Carinelli S, Prat J. Uterine tumors resembling ovarian sex cord tumors are polyphenotypic neoplasms with true sex cord differentiation. Mod Pathol. 2006;19:17-24. (Pubitemid 43250975)
143. Kabbani W, Deavers MT, Malpica A, et al. Uterine tumor resembling ovarian sex-cord tumor: report of a case mimicking cervical adenocarcinoma. Int J Gynecol Pathol. 2003;22:297-302. (Pubitemid 36750415)
144. Krishnamurthy S, Jungbluth AA, Busam KJ, et al. Uterine tumors resembling ovarian sex-cord tumors have an immunophenotype consistent with true sex-cord differentiation. Am J Surg Pathol. 1998;22:1078-1082. (Pubitemid 28411065)
145. McCluggage WG, McKenna M, McBride HA. CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors. Int J Gynecol Pathol. 2007;26:322-327. (Pubitemid 46986070)
146. Nogales FF, Isaac MA. Functioning uterine sex cord tumour. Histopathology. 2002;41:277-279. (Pubitemid 35013956)
147. Sutak J, Lazic D, Cullimore JE. Uterine tumour resembling an ovarian sex cord tumour. J Clin Pathol. 2005;58:888-890. (Pubitemid 41113402)
148. Kommoss F, Oliva E, Bhan AK, et al. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod Pathol. 1998;11:656-664. (Pubitemid 28335144)
149. McCluggage WG. Value of inhibin staining in gynecological pathology. Int J Gynecol Pathol. 2001;20:79-85. (Pubitemid 32041758)
150. Rishi M, Howard LN, Bratthauer GL, et al. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 1997;21:583-589. (Pubitemid 27213074)
151. Stewart CJ, Jeffers MD, Kennedy A. Diagnostic value of inhibin immunoreactivity in ovarian gonadal stromal tumours and their histological mimics. Histopathology. 1997;31:67-74. (Pubitemid 27314508)
152. Deavers MT, Malpica A, Liu J, et al. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol. 2003;16:584-590. (Pubitemid 36718440)
153. Stewart CJ, Nandini CL, Richmond JA. Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol. 2000;53:206-211. (Pubitemid 30163604)
154. Murray SK, Clement PB, Young RH. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol. 2005;29:157-166. (Pubitemid 40170633)
155. Ordi J, Schammel DP, Rasekh L, et al. Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases.
156. Liang SX, Patel K, Pearl M, et al. Sertoliform endometrioid carcinoma of the endometrium with dual immunophenotypes for epithelial membrane antigen and inhibin alpha: case report and literature review. Int J Gynecol Pathol. 2007;26:291-297. (Pubitemid 46986065)
157. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21:363-381. (Pubitemid 20141021)
158. Clement PB, Scully RE. Extrauterine mesodermal (mullerian) adenosarcoma: a clinicopathologic analysis of five cases. Am J Clin Pathol. 1978;69:276-283. (Pubitemid 8306784)
159. Eichhorn JH, Young RH, Clement PB, et al. Mesodermal (mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol. 2002;26:1243-1258.
160. Inoue M, Fukuda H, Tanizawa O. Adenosarcomas originating from sites other than uterine endometrium. Int J Gynaecol Obstet. 1995;48:299-306.
161. Soslow RA, Ali A, Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol. 2008;32:1013-1021.
162. Clement PB, Scully RE. Endometrial stromal sarcomas of the uterus with extensive endometrioid glandular differentiation: a report of three cases that caused problems in differential diagnosis. Int J Gynecol Pathol. 1992;11:163-173.
163. McCluggage WG, Ganesan R, Herrington CS. Endometrial stromal sarcomas with extensive endometrioid glandular differentiation: report of a series with emphasis on the potential for misdiagnosis and discussion of the differential diagnosis. Histopathology. 2009;54:365-373.
164. Parker RL, Dadmanesh F, Young RH, et al. Polypoid endometriosis: a clinicopathologic analysis of 24 cases and a review of the literature. Am J Surg Pathol. 2004;28:285-297. (Pubitemid 38269562)
165. Bhargava R, Shia J, Hummer AJ, et al. Distinction of endometrial stromal sarcomas from "hemangiopericytomatous" tumors using a panel of immunohistochemical stains. Mod Pathol. 2005;18:40-47. (Pubitemid 40128093)
166. Amant F, Schurmans K, Steenkiste E, et al. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma. Gynecol Oncol. 2004;93:680-685. (Pubitemid 38766055)
167. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90:170-176. (Pubitemid 37338093)
168. Mikami Y, Hata S, Kiyokawa T, et al. Expression of CD10 in malignant mullerian mixed tumors and adenosarcomas: an immunohistochemical study. Mod Pathol. 2002;15:923-930.
169. Coosemans A, Nik SA, Caluwaerts S, et al. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer. 2007;43:1630-1637. (Pubitemid 46891806)
170. Dupont J, Wang X, Marshall DS, et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol. 2004;94:449-455. (Pubitemid 39024552)
171. Franko A, Magliocco AM, Duan Q, et al. WT1 immunoprofiling and comparison of malignant Mullerian mixed tumors of the female genital tract. Int J Gynecol Pathol. 2010;29:452-458.
172. Kourea HP, Adonakis G, Androutsopoulos G, et al. Fallopian tube malignant mixed mullerian tumor (carcinosarcoma): a case report with immunohistochemical profiling. Eur J Gynaecol Oncol. 2008;29:538-542.
173. Scully RE, Young RH, Clement PB. Tumors of the ovary, malformed gonads, fallopian tubes and broad ligament. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology. Vol 23: 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1998.
174. Aguirre P, Thor AD, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors: an immunohistochemical study. Int J Gynecol Pathol. 1989;8:364-373. (Pubitemid 19260744)
175. Chadha S, van der Kwast TH. Immunohistochemistry of ovarian granulosa cell tumours: the value of tissue specific proteins and tumour markers. Virchows Arch A Pathol Anat Histopathol. 1989;414:439-445. (Pubitemid 19121766)
176. Costa MJ, DeRose PB, Roth LM, et al. Immunohistochemical phenotype of ovarian granulosa cell tumors: absence of epithelial membrane antigen has diagnostic value. Hum Pathol. 1994;25:60-66. (Pubitemid 24051826)
177. Costa MJ, Morris R, DeRose PB, et al. Histologic and immunohistochemical evidence for considering ovarian myxoma as a variant of the thecoma-fibroma group of ovarian stromal tumors. Arch Pathol Lab Med. 1993;117:802-808. (Pubitemid 23224896)
178. Costa MJ, Morris RJ, Wilson R, et al. Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas. Hum Pathol. 1992;23:787-797.
179. Farinola MA, Gown AM, Judson K, et al. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol. 2007;26:375-382. (Pubitemid 47476321)
180. Gitsch G, Kohlberger P, Hanzal E, et al. Immunohistochemical differentiation between ovarian granulosa cell tumors and ovarian carcinomas. Arch Gynecol Obstet. 1991;249:173-177.
181. Lastarria D, Sachdev RK, Babury RA, et al. Immunohistochemical analysis for desmin in normal and neoplastic ovarian stromal tissue. Arch Pathol Lab Med. 1990;114:502-505. (Pubitemid 20147435)
182. Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol. 2005;29:143-156. (Pubitemid 40170632)
183. Otis CN, Powell JL, Barbuto D, et al. Intermediate filamentous proteins in adult granulosa cell tumors. An immunohistochemical study of 25 cases. Am J Surg Pathol. 1992;16:962-968.
184. Park SH, Kim I. Histogenetic consideration of ovarian sex cord-stromal tumors analyzed by expression pattern of cytokeratins, vimentin, and laminin. Correlation studies with human gonads. Pathol Res Pract. 1994;190:449-456. (Pubitemid 24185157)
185. Riopel MA, Perlman EJ, Seidman JD, et al. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas. Int J Gynecol Pathol. 1998;17:46-53. (Pubitemid 28016702)
186. Santini D, Ceccarelli C, Leone O, et al. Smooth muscle differentiation in normal human ovaries, ovarian stromal hyperplasia and ovarian granulosa-stromal cells tumors. Mod Pathol. 1995;8:25-30.
187. Tiltman AJ, Haffajee Z. Sclerosing stromal tumors, thecomas, and fibromas of the ovary: an immunohistochemical profile. Int J Gynecol Pathol. 1999;18:254-258. (Pubitemid 29306983)
188. Vang R, Bague S, Tavassoli FA, et al. Signet-ring stromal tumor of the ovary: clinicopathologic analysis and comparison with Krukenberg tumor. Int J Gynecol Pathol. 2004;23:45-51. (Pubitemid 38018237)
189. Zhao C, Bratthauer GL, Barner R, et al. Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: A study of 160 cases. Am J Surg Pathol. 2007;31:255-266. (Pubitemid 46175027)
190. Zhao C, Vinh TN, McManus K, et al. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol. 2009;33:354-366.
191. Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type: a clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18:1102-1116. (Pubitemid 24337617)
192. McCluggage WG. Ovarian neoplasms composed of small round cells: a review. Adv Anat Pathol. 2004;11:288-296.
193. Barnoud R, Sabourin JC, Pasquier D, et al. Immunohistochemical expression of WT1 by desmoplastic small round cell tumor: a comparative study with other small round cell tumors. Am J Surg Pathol. 2000;24:830-836. (Pubitemid 30366270)
194. Charles AK, Moore IE, Berry PJ. Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour. Histopathology. 1997;30:312-314. (Pubitemid 27168788)
195. Zhang PJ, Goldblum JR, Pawel BR, et al. Immunophenotype of desmoplastic small round cell tumors as detected in cases with EWS-WT1 gene fusion product. Mod Pathol. 2003;16:229-235. (Pubitemid 36337429)
196. Parker LP, Duong JL, Wharton JT, et al. Desmoplastic small round cell tumor: report of a case presenting as a primary ovarian neoplasm. Eur J Gynaecol Oncol. 2002;23:199-202. (Pubitemid 34625324)
197. Young RH, Eichhorn JH, Dickersin GR, et al. Ovarian involvement by the intra-abdominal desmoplastic small round cell tumor with divergent differentiation: a report of three cases. Hum Pathol. 1992;23:454-464.
198. Slomovitz BM, Girotra M, Aledo A, et al. Desmoplastic small round cell tumor with primary ovarian involvement: case report and review. Gynecol Oncol. 2000;79:124-128.
199. Kawauchi S, Fukuda T, Miyamoto S, et al. Peripheral primitive neuroectodermal tumor of the ovary confirmed by CD99 immunostaining, karyotypic analysis, and RT-PCR for EWS/FLi-I chemeric RNA. Am J Surg Pathol. 1998;22:1417-1422. (Pubitemid 28499133)
200. Kim KJ, Jang BW, Lee SK, et al. A case of peripheral primitive neuroectodermal tumor of the ovary. Int J Gynecol Cancer. 2004;14:370-372.
201. Kleinman GM, Young RH, Scully RE. Primary neuroectodermal tumors of the ovary: a report of 25 cases. Am J Surg Pathol. 1993;17:764-778. (Pubitemid 23212009)
202. Nielsen GP, Oliva E, Young RH, et al. Primary ovarian rhabdomyosarcoma: a report of 13 cases. Int J Gynecol Pathol. 1998;17:113-119. (Pubitemid 28151008)
203. Young RH, Kozakewich HP, Scully RE. Metastatic ovarian tumors in children: a report of 14 cases and review of the literature. Int J Gynecol Pathol. 1993;12:8-19. (Pubitemid 23013906)
204. Young RH, Scully RE. Alveolar rhabdomyosarcoma metastatic to the ovary: a report of two cases and a discussion of the differential diagnosis of small cell malignant tumors of the ovary. Cancer. 1989;64:899-904. (Pubitemid 19188832)
205. Young RH, Scully RE. Sarcomas metastatic to the ovary: a report of 21 cases. Int J Gynecol Pathol. 1990;9:231-252. (Pubitemid 20298961)